Get access to our best features

Get access to our best features

Published 10 days ago

Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO - Viking Therapeutics (NASDAQ:VKTX)

Summary by Benzinga

Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.

0 Articles

0 Articles

All

Left

Center

Right

Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO - Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.

10 days ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated10 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Benzinga

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.